Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neurofibromatosis 2 × CNS × Clear all

Phase

Phase 2 16 Phase NA 7 Phase EARLY_PHASE1 2 Phase 1/2 2 Phase 3 1 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 15 Brain Neoplasms 12 Glioma 7 Carcinoma, Non-Small-Cell Lung 6 Recurrence 4 Astrocytoma 4 Spinal Cord Neoplasms 3 Neoplasms 3 Colorectal Neoplasms 3 Thyroid Carcinoma, Anaplastic 2 Thyroid Cancer, Papillary 2 Ovarian Neoplasms 2 Oligodendroglioma 2 Neurofibromatosis 1 2 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Multiple Myeloma 2 Medulloblastoma 2 Lung Neoplasms 2 Laryngeal Neoplasms 2 Hematologic Neoplasms 2 Erdheim-Chester Disease 2 Central Nervous System Neoplasms 2 cyclopia sequence 1 Vitamin D Deficiency 1 Thyroid Neoplasms 1 Stroke 1 Squamous Cell Carcinoma of Head and Neck 1 Spinal Cord Injuries 1 Somatostatinoma 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡